-
survival for some NET patients, but the long-term outlook for most patients with advanced NETs remains poor. This work will directly influence future clinical trial design in neuroendocrine cancer patients
-
full time (35 hours per week) fixed term from 15th August 2024 until 30th November 2025. Work pattern to include out of hours during days with sample collection. Salary: £32,332 - £34,980 per annum
-
analysis of transcriptomics data from publicly-available datasets, patient tumour lesions and animal tumours and the designing and production of tumour cell lines transfected with tumour antigens to be used
-
of 4* and 3*. This vibrant Department offers an outstanding work environment and is committed to growth, aiming for an expansion of over 50% in the next five years. The growth plan entails a substantial
-
and understanding to form relationships for future research collaboration. · To plan and manage own research activity, research resources in collaboration with others and contribute to the planning